Société de Therapeutique Marocaine Gelecekteki Büyüme
Future kriter kontrolleri 0/6
Société de Therapeutique Marocaine's EPS is expected to grow by 7.5% per annum.
Anahtar bilgiler
n/a
Kazanç büyüme oranı
7.5%
EPS büyüme oranı
Pharmaceuticals kazanç büyümesi | 19.4% |
Gelir büyüme oranı | n/a |
Gelecekteki özkaynak getirisi | n/a |
Analist kapsamı | None |
Son güncelleme | n/a |
Gelecekteki son büyüme güncellemeleri
Güncelleme yok
Recent updates
Kazanç ve Gelir Büyüme Tahminleri
Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
---|---|---|---|---|---|
6/30/2024 | 2,630 | 281 | 25 | 143 | N/A |
3/31/2024 | 2,558 | 272 | 4 | 122 | N/A |
12/31/2023 | 2,486 | 263 | -18 | 100 | N/A |
9/30/2023 | 2,411 | 262 | 21 | 121 | N/A |
6/30/2023 | 2,336 | 260 | 60 | 143 | N/A |
3/31/2023 | 2,319 | 264 | 73 | 150 | N/A |
12/31/2022 | 2,302 | 267 | 86 | 156 | N/A |
9/30/2022 | 2,268 | 286 | 129 | 197 | N/A |
6/30/2022 | 2,233 | 306 | 173 | 237 | N/A |
3/31/2022 | 2,145 | 293 | 219 | 282 | N/A |
12/31/2021 | 2,056 | 279 | 265 | 328 | N/A |
9/30/2021 | 1,998 | 264 | 199 | 258 | N/A |
6/30/2021 | 1,940 | 249 | 133 | 189 | N/A |
3/31/2021 | 1,869 | 240 | 84 | 141 | N/A |
12/31/2020 | 1,798 | 230 | 35 | 94 | N/A |
9/30/2020 | 1,737 | 233 | N/A | N/A | N/A |
6/30/2020 | 1,675 | 235 | N/A | N/A | N/A |
3/31/2020 | 1,680 | 227 | N/A | N/A | N/A |
12/31/2019 | 1,686 | 220 | 155 | 227 | N/A |
9/30/2019 | 1,647 | 173 | N/A | N/A | N/A |
6/30/2019 | 1,667 | 196 | N/A | N/A | N/A |
3/31/2019 | 1,629 | 207 | N/A | N/A | N/A |
12/31/2018 | 1,561 | 182 | 111 | 163 | N/A |
9/30/2018 | 1,544 | 208 | N/A | N/A | N/A |
6/30/2018 | 1,497 | 198 | N/A | N/A | N/A |
3/31/2018 | 1,456 | 174 | N/A | N/A | N/A |
12/31/2017 | 1,415 | 150 | N/A | 193 | N/A |
9/30/2017 | 1,400 | 153 | N/A | N/A | N/A |
6/30/2017 | 1,386 | 155 | N/A | N/A | N/A |
3/31/2017 | 1,356 | 152 | N/A | N/A | N/A |
12/31/2016 | 1,326 | 149 | N/A | 190 | N/A |
9/30/2016 | 1,261 | 135 | N/A | N/A | N/A |
6/30/2016 | 1,195 | 121 | N/A | N/A | N/A |
3/31/2016 | 1,175 | 119 | N/A | N/A | N/A |
12/31/2015 | 1,156 | 118 | N/A | 161 | N/A |
9/30/2015 | 1,155 | 115 | N/A | N/A | N/A |
6/30/2015 | 1,155 | 113 | N/A | N/A | N/A |
3/31/2015 | 1,138 | 102 | N/A | N/A | N/A |
12/31/2014 | 1,122 | 92 | N/A | 137 | N/A |
9/30/2014 | 1,125 | 95 | N/A | N/A | N/A |
6/30/2014 | 1,129 | 97 | N/A | N/A | N/A |
3/31/2014 | 1,124 | 107 | N/A | N/A | N/A |
12/31/2013 | 1,119 | 117 | N/A | 159 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: Insufficient data to determine if SOT's forecast earnings growth is above the savings rate (14.5%).
Kazançlar ve Piyasa: Insufficient data to determine if SOT's earnings are forecast to grow faster than the MA market
Yüksek Büyüme Kazançları: Insufficient data to determine if SOT's earnings are expected to grow significantly over the next 3 years.
Gelir ve Pazar: Insufficient data to determine if SOT's revenue is forecast to grow faster than the MA market.
Yüksek Büyüme Geliri: Insufficient data to determine if SOT's revenue is forecast to grow faster than 20% per year.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: Insufficient data to determine if SOT's Return on Equity is forecast to be high in 3 years time